Healthy
Conditions
Brief summary
The objectives of this study were to investigate relative BA at steady state and to investigate dose proportionality of pharmacokinetic parameters Relative BA at steady state: * Pramipexole 0.375 mg ER tablet q.d. versus pramipexole 0.125 mg IR tablet t.i.d. * Pramipexole 1.5 mg ER tablet q.d. versus pramipexole 0.5 mg IR tablet t.i.d. Dose proportionality of pharmacokinetic parameters: · Pramipexole ER dosages from 0.375 to 1.5 mg q.d.
Interventions
DRUGPramipexole ER tablet
DRUGPramipexole IR tablet
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* All subjects participating in the study are healthy male volunteers * Age between 20 and 40 years * Body mass index (BMI) between 17.6 and 26.4 kg/m2 * All volunteers must give written informed consent before screening to participate in this study and before first drug administration on Day 1 at Visit 2
Exclusion criteria
* Any findings of the medical examination (including blood pressure, pulse rate, ECG, and laboratory test parameters) of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Diseases of the central nervous system (such as epilepsy), psychiatric disorders or neurological disorders * History of orthostatic hypotension, fainting spells or blackouts * Chronic or acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\>24 hours) within at least one month or less than ten half-lives of the respective drug before the administration of investigational products * Use of any drugs which might influence the results of the trial within 7 days before the start of drug administration in the study or during the study period * Participation in another trial with an investigational drug (within 4 months before the start of drug administration) * Smoker (\>10 cigarettes or \>3 cigars or \>3 pipes/day and who cannot refrain from smoking at the trial site) * Alcohol abuse (\>40 g/day) * Drug abuse * Blood donation (≥100 mL within 4 weeks before drug administration or during the trial) * Excessive physical activities from 7 days before the start of drug administration to the end of this study * Any positive results in hepatitis B surface antigen (HBsAg), anti hepatitis B core (HBc) antibodies, anti hepatitis C virus (HCV) antibodies and human immunodeficiency virus (HIV) test The following
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCτ,ss=AUC0-24,ss for ER (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ=24 hours) | up to day 5 |
| AUC0-24,ss for IR (area under the concentration-time curve of the analyte in plasma over the time interval 0 to 24 hours at steady state) (This parameter was calculated as 3 times of AUC0-8,ss.) | up to 24 hours after drug administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUCτ,ss=AUC0-24,ss for ER (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ=24 hours) | up to 24 hours after drug administration | Dose proportionality (only for ER) |
| Cmax,ss (maximum measured concentration of the analyte in plasma at steady state) | up to day 5 | Dose proportionality (only for ER) |
| AUC0-24,ss for IR (area under the concentration-time curve of the analyte in plasma over the time interval 0 to 24 hours at steady state) (This parameter was calculated as 3 times of AUC0-8,ss.) | up to 24 hours after drug administration | — |
| Cmin,ss (minimum measured concentration of the analyte in plasma at steady state) | up to day 5 | — |
| PTF (peak-trough fluctuation) | up to day 5 | — |
| tmax,ss (time from last dosing to the maximum concentration of the analyte in plasma at steady state) | up to day 5 | — |
| Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose) | up to day 5 | — |
| Ae0-8,ss for IR (amount of analyte that is eliminated in urine from 0 to 8 hours at steady state) | up to 8 hours after drug administration | — |
| t1/2,ss (terminal half-life of the analyte in plasma at steady state) | up to day 5 | — |
| CL/F,ss (apparent clearance of the analyte in plasma at steady state after | up to day 5 | — |
| CLR,ss (renal clearance of the analyte at steady state determined over the dosing interval τ) | up to day 5 | — |
| Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following oral administration) | up to day 5 | — |
| AUC0-8,ss for IR (area under the concentration-time curve of the analyte in plasma over the time interval 0 to 8 hours at steady state) | up to 8 hours after drug administration | — |
| Number of subjects with adverse events | up to 7 days after last drug administration | — |
| Assessment of tolerability by investigator on a 4-point scale | Day 5 | — |
| Cavg (average concentration of the analyte in plasma at steady state) | up to day 5 | — |
| Ae0-24,ss (amount of analyte that is eliminated in urine from 0 to 24 hours at steady state) | up to 24 hours after drug administration | Relative BA |
Outcome results
None listed